| Primary |
| Pancreatic Carcinoma |
24.5% |
| Breast Cancer |
9.6% |
| Pancreatic Carcinoma Metastatic |
9.2% |
| Bladder Cancer |
7.1% |
| Product Used For Unknown Indication |
6.2% |
| Hodgkin's Disease |
5.6% |
| Non-small Cell Lung Cancer |
4.8% |
| Lung Neoplasm Malignant |
4.0% |
| Bile Duct Cancer |
3.7% |
| Non-hodgkin's Lymphoma |
3.4% |
| Adenocarcinoma Pancreas |
3.3% |
| Ovarian Cancer |
3.3% |
| Head And Neck Cancer |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.4% |
| Neoplasm Malignant |
2.0% |
| Chemotherapy |
1.7% |
| Breast Cancer Metastatic |
1.7% |
| Thymoma Malignant |
1.7% |
| Transitional Cell Carcinoma |
1.7% |
| Cholangiocarcinoma |
1.6% |
|
| Vomiting |
18.2% |
| Thrombocytopenia |
12.1% |
| Off Label Use |
8.5% |
| Pyrexia |
8.5% |
| White Blood Cell Count Decreased |
5.6% |
| Pneumonia |
4.7% |
| Thrombotic Microangiopathy |
4.7% |
| Pulmonary Embolism |
4.1% |
| Renal Failure Acute |
4.1% |
| White Blood Cell Count Increased |
3.5% |
| Pancytopenia |
2.9% |
| Posterior Reversible Encephalopathy Syndrome |
2.9% |
| Rash |
2.9% |
| Sepsis |
2.9% |
| Tachycardia |
2.6% |
| Thrombotic Thrombocytopenic Purpura |
2.6% |
| Deep Vein Thrombosis |
2.4% |
| Pain In Extremity |
2.4% |
| Neutrophil Count Decreased |
2.1% |
| Toxic Epidermal Necrolysis |
2.1% |
|
| Secondary |
| Non-small Cell Lung Cancer |
23.7% |
| Product Used For Unknown Indication |
12.0% |
| Drug Use For Unknown Indication |
10.3% |
| Pancreatic Carcinoma |
8.1% |
| Adenocarcinoma Pancreas |
6.0% |
| Breast Cancer |
5.6% |
| Prophylaxis |
4.5% |
| Pancreatic Carcinoma Metastatic |
3.9% |
| Pain |
2.9% |
| Hypertension |
2.8% |
| Hodgkin's Disease |
2.7% |
| Transitional Cell Carcinoma |
2.7% |
| Breast Cancer Metastatic |
2.3% |
| Non-hodgkin's Lymphoma |
2.3% |
| Lung Neoplasm Malignant |
2.2% |
| Nausea |
2.0% |
| Bladder Cancer |
1.6% |
| Diffuse Large B-cell Lymphoma |
1.5% |
| Ovarian Cancer |
1.4% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
|
| Thrombocytopenia |
17.2% |
| Vomiting |
11.7% |
| Pyrexia |
8.0% |
| Pulmonary Embolism |
7.9% |
| White Blood Cell Count Decreased |
7.4% |
| Neutropenia |
6.0% |
| Pneumonia |
4.4% |
| Anaemia |
4.2% |
| Sepsis |
3.8% |
| Death |
3.5% |
| Renal Failure Acute |
3.3% |
| Febrile Neutropenia |
2.9% |
| Pleural Effusion |
2.8% |
| Rash |
2.8% |
| Syncope |
2.6% |
| Weight Decreased |
2.5% |
| Disease Progression |
2.4% |
| Deep Vein Thrombosis |
2.4% |
| Urinary Tract Infection |
2.2% |
| Renal Failure |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.3% |
| Drug Use For Unknown Indication |
10.5% |
| Non-small Cell Lung Cancer |
9.2% |
| Breast Cancer |
9.0% |
| Pancreatic Carcinoma |
6.0% |
| Adenocarcinoma Pancreas |
5.1% |
| Metastases To Bone |
4.9% |
| Breast Cancer Metastatic |
4.6% |
| Chemotherapy |
4.1% |
| Pain |
4.1% |
| Pancreatic Carcinoma Metastatic |
3.5% |
| Lung Neoplasm Malignant |
3.0% |
| Ovarian Cancer |
2.5% |
| Nausea |
2.0% |
| Prophylaxis Of Nausea And Vomiting |
1.9% |
| Bile Duct Cancer |
1.6% |
| Lung Adenocarcinoma |
1.6% |
| Hypertension |
1.4% |
| Constipation |
1.3% |
| Prophylaxis |
1.3% |
|
| Rash |
10.7% |
| Vomiting |
10.0% |
| Malignant Neoplasm Progression |
9.1% |
| Pyrexia |
6.6% |
| Death |
6.4% |
| Disease Progression |
6.1% |
| Pulmonary Embolism |
5.2% |
| Weight Decreased |
5.0% |
| Ulcer |
4.8% |
| Osteonecrosis |
3.9% |
| Pneumonia |
3.9% |
| Dyspnoea |
3.4% |
| Thrombocytopenia |
3.4% |
| White Blood Cell Count Decreased |
3.4% |
| Neutropenia |
3.2% |
| Platelet Count Decreased |
3.2% |
| White Blood Cell Count Increased |
3.2% |
| Pleural Effusion |
3.0% |
| Tachycardia |
3.0% |
| Nausea |
2.7% |
|
| Interacting |
| Bladder Cancer |
23.7% |
| Transitional Cell Carcinoma |
23.7% |
| Chemotherapy |
13.6% |
| Malignant Hydatidiform Mole |
8.5% |
| General Anaesthesia |
7.6% |
| Adenocarcinoma Pancreas |
2.5% |
| Breast Cancer |
2.5% |
| Lung Adenocarcinoma Stage Iv |
2.5% |
| Non-small Cell Lung Cancer |
2.5% |
| Essential Hypertension |
1.7% |
| Macular Degeneration |
1.7% |
| Pancreas Carcinoma |
1.7% |
| Urethral Cancer |
1.7% |
| Atrial Fibrillation |
0.8% |
| Cancer Pain |
0.8% |
| Drug Use For Unknown Indication |
0.8% |
| Hypertension |
0.8% |
| Lung Adenocarcinoma |
0.8% |
| Musculoskeletal Chest Pain |
0.8% |
| Product Used For Unknown Indication |
0.8% |
|
| Dizziness |
33.3% |
| Pancreatic Carcinoma |
8.3% |
| Renal Impairment |
8.3% |
| Reversible Posterior Leukoencephalopathy Syndrome |
8.3% |
| Headache |
4.2% |
| Hepatitis |
4.2% |
| Musculoskeletal Pain |
4.2% |
| Myelodysplastic Syndrome |
4.2% |
| Prothrombin Time Prolonged |
4.2% |
| Renal Failure |
4.2% |
| Sudden Hearing Loss |
4.2% |
| Supraventricular Tachycardia |
4.2% |
| Visual Disturbance |
4.2% |
| Vomiting |
4.2% |
|
